Home › Companies › Rocket Pharmaceuticals, Inc. › 2025-2026

Rocket Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Rocket Pharmaceuticals, Inc.’s Form 8-K, filed 2026-05-21 (Item 5.07 on EDGAR). Page generated 02 October 2026.

10Reported items
176Asset managers
1,795Fund votes
2026-05-20Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Rocket Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Rocket Pharmaceuticals, Inc.

These tallies are Rocket Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-21 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Rocket Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2026-05-20
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Peter Fong, M.D.	62,067,824	--	--	1,216,320	17,490,515	Majority: yes
Elect Director: Carsten Boess	62,711,345	--	--	572,799	17,490,515	Majority: yes
Elect Director: Mikael Dolsten, M.D., Ph.D.	59,500,907	--	--	3,783,237	17,490,515	Majority: yes
Elect Director: Fady Malik, M.D., Ph.D.	62,755,875	--	--	528,269	17,490,515	Majority: yes
Elect Director: Gaurav Shah, M.D.	62,808,593	--	--	475,551	17,490,515	Majority: yes
Elect Director: David P. Southwell	43,172,112	--	--	20,112,032	17,490,515	Majority: yes
Elect Director: Roderick Wong, M.D.	62,699,331	--	--	584,813	17,490,515	Majority: yes
Proposal Four – Stock Option Exchange Program The Company's stockholders approved the proposed stock option exchange program as described in the 2026 Proxy Statement. The final votes were:	45,582,445	17,615,213	86,486	--	17,490,515	Majority: yes

Source: Rocket Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-05-21 — read the filing on EDGAR.

How asset managers voted at the Rocket Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 176 asset managers that disclosed a Rocket Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Rocket Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. A non-binding, advisory vote on the compensation of our named executive officers;

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

98% fund support · no official result

FOR 98%

The 172 asset managers below cast 98% of the shares they voted on this item FOR (63,527,366 for, 1,058,257 against).

FOR: 63,527,366 (98.4%)AGAINST: 1,058,257 (1.6%)ABSTAIN: 6,214 (0.0%)

Largest asset managers voting on “A non-binding, advisory vote on the compensation of our named executive officers;” at Rocket Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
RTW INVESTMENTS, LP	16,734,217	0	For
Vanguard	9,048,402	3	For
State Street	4,261,811	1,698	For
BlackRock	3,623,408	173,625	For
Newtyn Management, LLC	2,649,999	0	For
Nuveen	2,433,910	0	For
TIAA	2,408,157	0	For
Fidelity	1,903,622	0	For
MAVERICK CAPITAL LTD	1,755,035	0	For
AQR	1,751,710	0	For
DE Shaw	1,597,419	0	For
Federated Hermes	1,588,553	0	For
T. Rowe Price	1,565,648	0	For
Charles Schwab	1,445,511	0	For
Two Sigma	1,442,408	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,382,721	0	For
MARSHALL WACE, LLP	1,189,886	0	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	1,171,226	0	For
Aberdeen	0	735,332	Against
Goldman Sachs	514,692	0	For
Bridge Builder Trust	459,875	0	For
Woodline Partners LP	440,963	0	For
Northern Trust	370,471	0	For
M28 Capital Management LP	281,161	0	For
Equitable	248,116	0	For

Showing the 25 largest of 172 asset managers. See all 172 in the interactive database.

2. The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Carsten Boess

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%

FOR: 62,711,345WITHHELD: 572,799

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Carsten Boess”): 62,711,345 for, 572,799 withheld, per its Form 8-K filed 2026-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 109,193,549 outstanding shares: 57% for, 0.6% withheld (58% of the company cast a for/withheld vote).

The 51 asset managers below cast 100% of the shares they voted on this item FOR (20,503,799 for, 0 against).

FOR 99.4%

FOR: 20,503,799 (99.4%)ABSTAIN: 116,444 (0.6%)

Largest asset managers voting on “The election of seven directors named in the proxy statement to hold office until the Company's annual meeting” at Rocket Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	8,402,412	11,094	For
State Street	2,806,686	0	For
TIAA	2,408,157	0	For
BlackRock	1,482,300	0	For
Fidelity	1,480,546	0	For
Charles Schwab	721,989	0	For
Federated Hermes	576,320	0	For
T. Rowe Price	546,938	0	For
Bridge Builder Trust	459,875	0	For
Equitable	142,766	105,350	For
JPMorgan	172,900	0	For
Direxion Shares ETF Trust	151,545	0	For
QUANTITATIVE MASTER SERIES LLC	131,134	0	For
Dimensional	109,871	0	For
ETFis Series Trust I	85,177	0	For
Global X	80,909	0	For
ProShares	80,431	0	For
Lincoln Financial	75,844	0	For
AIG/SunAmerica	62,116	0	For
Goldman Sachs	61,960	0	For
Delaware/Macquarie	58,000	0	For
Brighthouse	57,129	0	For
American Century	55,389	0	For
John Hancock	49,130	0	For
Pacific Life	33,958	0	For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

3. The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: David P. Southwell

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

68% Majority: yes · of votes cast

FOR 68%WITHHELD 32%

FOR: 43,172,112WITHHELD: 20,112,032

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David P. Southwell”): 43,172,112 for, 20,112,032 withheld, per its Form 8-K filed 2026-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 109,193,549 outstanding shares: 40% for, 18% withheld (58% of the company cast a for/withheld vote).

The 51 asset managers below cast 100% of the shares they voted on this item FOR (13,024,168 for, 0 against).

FOR 63%ABSTAIN 37%

FOR: 13,024,168 (63.2%)ABSTAIN: 7,596,075 (36.8%)

Largest asset managers voting on “The election of seven directors named in the proxy statement to hold office until the Company's annual meeting” at Rocket Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	8,402,368	11,138	For
State Street	0	2,806,686	Abstain
TIAA	0	2,408,157	Abstain
BlackRock	1,482,300	0	For
Fidelity	1,480,546	0	For
Charles Schwab	0	721,989	Abstain
Federated Hermes	576,320	0	For
T. Rowe Price	0	546,938	Abstain
Bridge Builder Trust	459,875	0	For
Equitable	125,810	122,306	For
JPMorgan	172,900	0	For
Direxion Shares ETF Trust	0	151,545	Abstain
QUANTITATIVE MASTER SERIES LLC	131,134	0	For
Dimensional	0	109,871	Abstain
ETFis Series Trust I	0	85,177	Abstain
Global X	0	80,909	Abstain
ProShares	0	80,431	Abstain
Lincoln Financial	17,143	58,701	Abstain
AIG/SunAmerica	0	62,116	Abstain
Goldman Sachs	61,960	0	For
Delaware/Macquarie	0	58,000	Abstain
Brighthouse	26,145	30,984	Abstain
American Century	0	55,389	Abstain
John Hancock	0	49,130	Abstain
Pacific Life	33,958	0	For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

4. The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Fady Malik, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 62,755,875WITHHELD: 528,269

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Fady Malik, M.D., Ph.D.”): 62,755,875 for, 528,269 withheld, per its Form 8-K filed 2026-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 109,193,549 outstanding shares: 57% for, 0.5% withheld (58% of the company cast a for/withheld vote).

The 51 asset managers below cast 100% of the shares they voted on this item FOR (20,507,361 for, 0 against).

FOR 99.4%

FOR: 20,507,361 (99.5%)ABSTAIN: 112,882 (0.5%)

Largest asset managers voting on “The election of seven directors named in the proxy statement to hold office until the Company's annual meeting” at Rocket Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	8,405,974	7,532	For
State Street	2,806,686	0	For
TIAA	2,408,157	0	For
BlackRock	1,482,300	0	For
Fidelity	1,480,546	0	For
Charles Schwab	721,989	0	For
Federated Hermes	576,320	0	For
T. Rowe Price	546,938	0	For
Bridge Builder Trust	459,875	0	For
Equitable	142,766	105,350	For
JPMorgan	172,900	0	For
Direxion Shares ETF Trust	151,545	0	For
QUANTITATIVE MASTER SERIES LLC	131,134	0	For
Dimensional	109,871	0	For
ETFis Series Trust I	85,177	0	For
Global X	80,909	0	For
ProShares	80,431	0	For
Lincoln Financial	75,844	0	For
AIG/SunAmerica	62,116	0	For
Goldman Sachs	61,960	0	For
Delaware/Macquarie	58,000	0	For
Brighthouse	57,129	0	For
American Century	55,389	0	For
John Hancock	49,130	0	For
Pacific Life	33,958	0	For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

5. The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Gaurav Shah, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 62,808,593WITHHELD: 475,551

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Gaurav Shah, M.D.”): 62,808,593 for, 475,551 withheld, per its Form 8-K filed 2026-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 109,193,549 outstanding shares: 58% for, 0.5% withheld (58% of the company cast a for/withheld vote).

The 51 asset managers below cast 100% of the shares they voted on this item FOR (20,612,710 for, 0 against).

FOR 99.9%

FOR: 20,612,710 (100.0%)ABSTAIN: 7,533 (0.0%)

Largest asset managers voting on “The election of seven directors named in the proxy statement to hold office until the Company's annual meeting” at Rocket Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	8,405,973	7,533	For
State Street	2,806,686	0	For
TIAA	2,408,157	0	For
BlackRock	1,482,300	0	For
Fidelity	1,480,546	0	For
Charles Schwab	721,989	0	For
Federated Hermes	576,320	0	For
T. Rowe Price	546,938	0	For
Bridge Builder Trust	459,875	0	For
Equitable	248,116	0	For
JPMorgan	172,900	0	For
Direxion Shares ETF Trust	151,545	0	For
QUANTITATIVE MASTER SERIES LLC	131,134	0	For
Dimensional	109,871	0	For
ETFis Series Trust I	85,177	0	For
Global X	80,909	0	For
ProShares	80,431	0	For
Lincoln Financial	75,844	0	For
AIG/SunAmerica	62,116	0	For
Goldman Sachs	61,960	0	For
Delaware/Macquarie	58,000	0	For
Brighthouse	57,129	0	For
American Century	55,389	0	For
John Hancock	49,130	0	For
Pacific Life	33,958	0	For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

6. The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Mikael Dolsten, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 59,500,907WITHHELD: 3,783,237

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Mikael Dolsten, M.D., Ph.D.”): 59,500,907 for, 3,783,237 withheld, per its Form 8-K filed 2026-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 109,193,549 outstanding shares: 54.5% for, 3% withheld (58% of the company cast a for/withheld vote).

The 51 asset managers below cast 100% of the shares they voted on this item FOR (18,688,549 for, 0 against).

FOR 91%9%

FOR: 18,688,549 (90.6%)ABSTAIN: 1,931,695 (9.4%)

Largest asset managers voting on “The election of seven directors named in the proxy statement to hold office until the Company's annual meeting” at Rocket Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	8,409,937	3,570	For
State Street	2,806,686	0	For
TIAA	2,408,157	0	For
BlackRock	1,482,300	0	For
Fidelity	1,480,546	0	For
Charles Schwab	0	721,989	Abstain
Federated Hermes	0	576,320	Abstain
T. Rowe Price	546,938	0	For
Bridge Builder Trust	36,908	422,967	Abstain
Equitable	142,766	105,350	For
JPMorgan	172,900	0	For
Direxion Shares ETF Trust	151,545	0	For
QUANTITATIVE MASTER SERIES LLC	131,134	0	For
Dimensional	109,871	0	For
ETFis Series Trust I	85,177	0	For
Global X	0	80,909	Abstain
ProShares	80,431	0	For
Lincoln Financial	75,844	0	For
AIG/SunAmerica	62,116	0	For
Goldman Sachs	61,960	0	For
Delaware/Macquarie	58,000	0	For
Brighthouse	57,129	0	For
American Century	55,389	0	For
John Hancock	49,130	0	For
Pacific Life	33,958	0	For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

7. The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Peter Fong, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 62,067,824WITHHELD: 1,216,320

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Peter Fong, M.D.”): 62,067,824 for, 1,216,320 withheld, per its Form 8-K filed 2026-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 109,193,549 outstanding shares: 57% for, 1% withheld (58% of the company cast a for/withheld vote).

The 51 asset managers below cast 100% of the shares they voted on this item FOR (20,022,303 for, 0 against).

FOR 97%

FOR: 20,022,303 (97.1%)ABSTAIN: 597,941 (2.9%)

Largest asset managers voting on “The election of seven directors named in the proxy statement to hold office until the Company's annual meeting” at Rocket Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	8,409,942	3,565	For
State Street	2,806,686	0	For
TIAA	2,408,157	0	For
BlackRock	1,482,300	0	For
Fidelity	1,480,546	0	For
Charles Schwab	721,989	0	For
Federated Hermes	576,320	0	For
T. Rowe Price	0	546,938	Abstain
Bridge Builder Trust	459,875	0	For
Equitable	231,160	16,956	For
JPMorgan	172,900	0	For
Direxion Shares ETF Trust	151,545	0	For
QUANTITATIVE MASTER SERIES LLC	131,134	0	For
Dimensional	109,871	0	For
ETFis Series Trust I	85,177	0	For
Global X	80,909	0	For
ProShares	80,431	0	For
Lincoln Financial	75,844	0	For
AIG/SunAmerica	62,116	0	For
Goldman Sachs	61,960	0	For
Delaware/Macquarie	58,000	0	For
Brighthouse	57,129	0	For
American Century	55,389	0	For
John Hancock	25,595	23,535	For
Pacific Life	33,958	0	For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

8. The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Roderick Wong, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%

FOR: 62,699,331WITHHELD: 584,813

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Roderick Wong, M.D.”): 62,699,331 for, 584,813 withheld, per its Form 8-K filed 2026-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 109,193,549 outstanding shares: 57% for, 0.6% withheld (58% of the company cast a for/withheld vote).

The 51 asset managers below cast 100% of the shares they voted on this item FOR (20,507,360 for, 0 against).

FOR 99.4%

FOR: 20,507,360 (99.5%)ABSTAIN: 112,883 (0.5%)

Largest asset managers voting on “The election of seven directors named in the proxy statement to hold office until the Company's annual meeting” at Rocket Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	8,405,973	7,533	For
State Street	2,806,686	0	For
TIAA	2,408,157	0	For
BlackRock	1,482,300	0	For
Fidelity	1,480,546	0	For
Charles Schwab	721,989	0	For
Federated Hermes	576,320	0	For
T. Rowe Price	546,938	0	For
Bridge Builder Trust	459,875	0	For
Equitable	142,766	105,350	For
JPMorgan	172,900	0	For
Direxion Shares ETF Trust	151,545	0	For
QUANTITATIVE MASTER SERIES LLC	131,134	0	For
Dimensional	109,871	0	For
ETFis Series Trust I	85,177	0	For
Global X	80,909	0	For
ProShares	80,431	0	For
Lincoln Financial	75,844	0	For
AIG/SunAmerica	62,116	0	For
Goldman Sachs	61,960	0	For
Delaware/Macquarie	58,000	0	For
Brighthouse	57,129	0	For
American Century	55,389	0	For
John Hancock	49,130	0	For
Pacific Life	33,958	0	For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

9. The approval of the proposed stock option exchange program; and

COMPENSATIONMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

72% Majority: yes · of votes cast

FOR 72%AGAINST 28%

FOR: 45,582,445AGAINST: 17,615,213

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Proposal Four – Stock Option Exchange Program The Company's stockholders approved the proposed stock option exchange program as described in the 2026 Proxy Statement. The final votes were:”): 45,582,445 for, 17,615,213 against, per its Form 8-K filed 2026-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 109,193,549 outstanding shares: 42% for, 16% against (58% of the company cast a for/against vote).

The 51 asset managers below cast 69% of the shares they voted on this item FOR (14,219,383 for, 6,400,860 against).

FOR 69%AGAINST 31%

FOR: 14,219,383 (69.0%)AGAINST: 6,400,860 (31.0%)

Largest asset managers voting on “The approval of the proposed stock option exchange program; and” at Rocket Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	8,405,935	7,571	For
State Street	0	2,806,686	Against
TIAA	2,408,157	0	For
BlackRock	1,482,300	0	For
Fidelity	406,718	1,073,828	Against
Charles Schwab	721,989	0	For
Federated Hermes	0	576,320	Against
T. Rowe Price	0	546,938	Against
Bridge Builder Trust	36,908	422,967	Against
Equitable	125,810	122,306	For
JPMorgan	172,900	0	For
Direxion Shares ETF Trust	0	151,545	Against
QUANTITATIVE MASTER SERIES LLC	131,134	0	For
Dimensional	0	109,871	Against
ETFis Series Trust I	0	85,177	Against
Global X	80,909	0	For
ProShares	0	80,431	Against
Lincoln Financial	17,143	58,701	Against
AIG/SunAmerica	0	62,116	Against
Goldman Sachs	61,960	0	For
Delaware/Macquarie	0	58,000	Against
Brighthouse	26,145	30,984	Against
American Century	0	55,389	Against
John Hancock	0	49,130	Against
Pacific Life	33,958	0	For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

10. The ratification of the appointment of Eisner Amper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026;

AUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 51 asset managers below cast 99.9% of the shares they voted on this item FOR (20,620,242 for, 1 against).

FOR: 20,620,242 (100.0%)AGAINST: 1 (0.0%)

Largest asset managers voting on “The ratification of the appointment of Eisner Amper LLP as the Company's independent registered public account” at Rocket Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	8,413,505	1	For
State Street	2,806,686	0	For
TIAA	2,408,157	0	For
BlackRock	1,482,300	0	For
Fidelity	1,480,546	0	For
Charles Schwab	721,989	0	For
Federated Hermes	576,320	0	For
T. Rowe Price	546,938	0	For
Bridge Builder Trust	459,875	0	For
Equitable	248,116	0	For
JPMorgan	172,900	0	For
Direxion Shares ETF Trust	151,545	0	For
QUANTITATIVE MASTER SERIES LLC	131,134	0	For
Dimensional	109,871	0	For
ETFis Series Trust I	85,177	0	For
Global X	80,909	0	For
ProShares	80,431	0	For
Lincoln Financial	75,844	0	For
AIG/SunAmerica	62,116	0	For
Goldman Sachs	61,960	0	For
Delaware/Macquarie	58,000	0	For
Brighthouse	57,129	0	For
American Century	55,389	0	For
John Hancock	49,130	0	For
Pacific Life	33,958	0	For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

Largest Rocket Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked by the number of Rocket Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 109,193,549 shares outstanding at the time of that meeting.

Top Rocket Pharmaceuticals, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	RTW INVESTMENTS, LP	15.33%
2	Vanguard	8.29%
3	State Street	3.90%
4	BlackRock	3.48%
5	Newtyn Management, LLC	2.43%
6	Nuveen	2.23%
7	TIAA	2.21%
8	Fidelity	1.74%
9	MAVERICK CAPITAL LTD	1.61%
10	AQR	1.60%

Reported Rocket Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Rocket Pharmaceuticals, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Roderick Wong, M.D.	16.88%	DEF14A
RTW Investments, LP	16.66%	DEF14A
Vanguard Group	7.83%	13F
BlackRock	7.18%	13F
State Street	4.11%	13F
Morgan Stanley	3.61%	13F
Gaurav Shah, M.D.	2.95%	DEF14A
Geode Capital	2.00%	13F
D.E. Shaw	1.99%	13F
Goldman Sachs	1.70%	13F

Percentages above are of 109,193,549 shares outstanding, as reported by Rocket Pharmaceuticals, Inc. on its Form 10-Q dated 2026-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Rocket Pharmaceuticals, Inc.’s 10-Q dated 2026-05-01. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Rocket Pharmaceuticals, Inc.'s shareholder meeting held 2026-05-20, in the 2025-2026 proxy season, 176 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,795 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Rocket Pharmaceuticals, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — A non-binding, advisory vote on the compensation of our named executive officers; — the reporting funds cast 98% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Rocket Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).